• Moleculin Biotech reported interim, unblinded efficacy results from its Phase 2/3 MIRACLE trial of Annamycin in relapsed or refractory AML.
• The early readout showed Annamycin regimens produced more remissions than the control regimen, supporting continued development.
• The independent monitoring committee recommended the study continue as planned, with no experimental dose arm dropped at this stage.
• Enrollment continues in Part A toward dose selection, with the chosen dose expected to advance into the pivotal portion of the trial.
• The efficacy interim results were presented in this release, with additional trial data pending final Part A database review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-022088), on June 30, 2026, and is solely responsible for the information contained therein.